Press Releases

– Completed transformational private placement for up to $113.6 million, including $42.2 million upfront – – Generated Q1 2023 CGuard EPS revenue of $1.2 million, an increase of 6.7% over Q1 2022 despite the temporary expiration of the Company’s CE Mark certification until mid-March – – Resumed shipments of CGuard EPS to CE Mark territories… Read More

Led by Marshall Wace with participation from OrbiMed, Rosalind, Nantahala, Soleus, Velan and certain InspireMD Board members   $42.2 million financing upfront with up to an additional $71.4 million tied to exercise of milestone-driven warrants   Tel Aviv, Israel and Miami, Florida — May 15, 2023 – InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS)… Read More

  -Conference call and webcast to be held at 8:30 a.m. EDT-  Tel Aviv, Israel— May 12, 2023 – InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke prevention, announced today that it will host its conference call and webcast to… Read More

  -Conference call and webcast to be held at 8:30 a.m. EDT-   Tel Aviv, Israel— May 5, 2023 – InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke prevention, announced today it will now report first quarter 2023 financial results… Read More

  Procedure performed as part of the company’s ongoing CGuardians U.S. Investigational Device Exemption (IDE) trial designed to support potential U.S. marketing approval of the CGuard stent system. CGuardians enrollment on track to be completed by the end of Q2 2023   Tel Aviv, Israel — May 1, 2023 – InspireMD, Inc. (Nasdaq: NSPR), developer of… Read More

Tel Aviv, Israel— April 27, 2023 – InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke prevention, announced today it will report first quarter 2023 financial results on Tuesday, May 9th, 2023, before the financial markets open.  Management will host a… Read More

– 2022 CGuard EPS revenue of $5.1 million increased 18.9% over 2021 – – Resumed shipments of CGuard EPS to CE Mark territories under the pre-existing Medical Device Directive (MDD) regulatory framework; Company anticipates re-certification under new Medical Device Regulation (MRD) framework in coming weeks – – Continued enrollment in the C-Guardian US IDE trial,… Read More

  Mr. Tommasoli formerly served as the Company’s Senior Vice President of Global Sales & Marketing since 2020 and has significant prior commercial leadership experience at Integra LifeSciences and St. Jude Medical  Tel Aviv, Israel — March 20, 2023 – InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the… Read More

-Conference call and webcast to be held at 8:30 a.m. EDT- Tel Aviv, Israel— March 2, 2023 – InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke prevention, announced today it will report fourth quarter and full-year 2022 financial results on… Read More

Seasoned veteran in vascular space adds significant expertise in U.S. commercial market readiness and global strategic marketing Tel Aviv, Israel — February 14, 2023 – InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that it has hired medical device commercial veteran Shane Gleason… Read More